Category: News
-
Suppressed protein halted melanoma metastasis
This is amazing!! They have found that inhibiting a specific protein eliminated metastasis of melanoma in laboratory experiments, a finding that could lead to targeted therapies to stop metastasis in not only melanoma but, potentially, a broad range of cancers. WOW! We are getting close Read more http://www.oncologynurseadvisor.com/suppressed-protein-halted-melanoma-metastasis/article/271157/
-
Dabrafenib and Trametinib
Two drugs under review by the FDA—dabrafenib and trametinib—seem to slow development of treatment resistance in patients with metastatic malignant melanoma. http://www.pharmacytimes.com/news/Combatting-Treatment-Resistance-in-Metastatic-Melanoma-Therapy
-
InteRNA Gets Nod for US Patent, Plans IND for miRNA Melanoma Drug in Late 2013
Doug Macron is the editor of GenomeWeb’s Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail him here or follow his GenomeWeb Twitter account at @Genesilencing.
-
Rules of Engagement
I am a melanoma thriver who was diagnosed with Stage IV Melanoma in November 2009 Learning how to advocate is key to survival. There is no “manual” available. Research, evaluate clinical trials, and determine the right path for you and your disease. The medical community is close to finding a solution to this disease. It’s just…
-
New Combination Therapys
Combination therapy of Thymosin with dacarbazine and interferon alpha. Thymosin is a peptide released by the thymus gland. http://www.ncbi.nlm.nih.gov/pubmed/23050811 Yervoy causes inflammation in Melanoma. Teaming Yervoy with a T-cell therapy makes a lot of sense… http://www.chemotherapyadvisor.com/inflammation-induces-melanomas-invisibility-to-t-cell-immunotherapy/article/263930/
-
Stem Cell Hypothesis in Melanoma
Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. Abstract: Whether tumorigenic cancer stem cells (CSCs) exist in melanoma has been the focus of much controversy in recent years. A number of studies have pointed to the existence of melanoma cell sub-populations that act as CSCs and can be distinguished from other…
-
Yervoy, Zelboraf & anti-PD1.
New Metastatic Melanoma Therapies Create Hope for Patients, Key Role for Oncology Nurses Lauren M. Green Published Online: Monday, October 8, 2012 Not surprisingly, melanoma nurse practitioner Rajni Kannan is passionate about helping her patients at NYU’s Cancer Institute to fight this devastating disease. That’s why Kannan, BS, MS, RN, ANP-BC, is excited about…
-
Study Shows Fat Tissue Influences Tumor Growth Despite Diet
Overweight cancer patients generally have a worse prognosis compared to their leaner counterparts. A new study published today in Cancer Research suggests a mechanism for the link between obesity and cancer. “Our study for the first times proves that excess fat tissue can directly promote cancer progression irrespective of the diet responsible for obesity onset,”…
-
Companies Target Melanoma Drug Delevelopment
“There are today 242 companies plus partners developing 273 drugs targeting melanoma in development.” Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%. There are today…
-
Resources
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed venenatis facilisis nulla quis tempor. Nulla sem metus, convallis eget feugiat in, congue aliquam leo. Nulla facilisi. Etiam viverra luctus nulla, in venenatis ante auctor sit amet. Phasellus in lacus orci. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Ut in enim…